Project: Integration of knowledge and biobank resources in comprehensive translational approach for personalized prevention and treatment of metabolic disorders

Acronym: INTEGROMED

Call for proposal: H2020-WIDESPREAD-2018-2020

Contract number: 857572

Implementation period: 1 October 2019 – 31 March 2023

Project coordinator: Latvijas Biomedicinas petijumu un studiju centrs (LBMC)

Project partners:

                                  University of Dundee (UNIVDUN)

                                  Weizmann institute of science LTD (WEIZMANN)

                                  Lunds Universitet (ULUND)

Project web page: https://integromed.net/ 

Leader of Latvian team: Dr. biol., Assoc. prof. Jānis Kloviņš

Total Costs: 800 000.00 EUR

Summary

INTEGROMED is aiming to provide LBMC with the opportunity to integrate the experience of research excellence institutions and existing resources by creating a research and innovation network with three internationally leading organizations in the translational medicine area – University of Dundee, Lund University, and Weizmann Institute of Science. The strategy of INTEGROMED is to increase excellence and develop sustainable approach targeting virtually all aspects of translational medicine including the optimal use of clinical and biobank resources, integration of different omics in systemic workflow, reaching development of bedside applications and fostering entrepreneurism. Project has a strong focus on study of metabolic disorders including type 2 diabetes, however the training, mentoring and stuff exchange activities as well as practical outcomes will be available for other fields including researchers, clinicians and other stakeholders in Latvia, promoting the implementation of the developed strategies at larger scale. The result of project will be accomplished by following three main objectives. (1) To improve and optimize the use of resources provided by large biobanks and prospective cohorts in combination with national health care system, improve knowledge in establishment of clinical studies for development of precision medicine approaches. (2) To strengthen collaboration-based training of specialists in areas of multi-omics approaches, bioinformatics, and modelling to increase excellence in implementing cutting edge multi omics technologies in such areas as genomics, methylation and expression profile, microbiome and metabolome analysis. (3) To elaborate a long-term strategy and sustainability plan involving all relevant stakeholders, ensure development and training in clinical applications and entrepreneurial skills to build an innovation ecosystem around LBMC.